Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20170208032451N1
IRCT20170208032451N1
Not yet recruiting
Phase 1

Clinical evaluation of immunogenic adjuvant therapy with dendritic cells loaded with autologous tumor mRNA in patients with gastric cancer

Mashhad University of Medical Sciences0 sites5 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Mashhad University of Medical Sciences
Enrollment
5
Status
Not yet recruiting
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients with gastric adenocarcinoma whose histologically advanced malignancy (spread of cancer cells to lymph nodes and tumor metastasis) has been confirmed and they have filled out the informed consent form
  • •The patient must be over 18 years old at the time of diagnosis.
  • •Natural laboratory parameters, including these tests: Protein C\& S, D\-Dimer, VWF, CPK,LDH, TI, ALP, Lipase, Amylase, GGT, OB,CBC diff, Hgb electrophoresis, Serum Iron, Transferrin saturation, TIBC, CH50 (total complement), ESR, CRP, ACE, ANA, Anti CCP, RF, Auto antibodies, UA, Uric acid, Cr, Urea, SGPT, SGOT, Bilirubin, Albumin, Lipid profile, ACTH, Cortisol, FBS, HbA1c, OGT , ACTH, Cortisol, FBS, HbA1c, OGTT, Insulin, PTH, GH, Calcitonin, TFT, Testosterone, LH, FSH, Estrogen, Progestrone, PRL.
  • •To start immunotherapy, at least 4 weeks must have passed since the last course of chemotherapy or radiotherapy, and all the side effects of chemotherapy must be eliminated.
  • •Functional condition according to Karnowski criteria should be more than 60%
  • •Expected survival rate more than 6 months

Exclusion Criteria

  • •brain metastasis
  • •autoimmune diseases
  • •Abnormal function of heart, liver, kidney, brain and other important organs

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable.Pancreatic cancer
JPRN-C000000414Yokohama City University Hospital10
Active, not recruiting
Phase 1
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract.The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of divergent histologies (i.e. squamous-cell tumor, adenocarcinoma, small cell carcinoma, micropapillary variant) may be acceptable provided that there is an important prevalence (> 90%) of urothelial component.MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-001028-32-FRCHU DE NIMES99
Active, not recruiting
Phase 1
Immunotherapy in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporation in curative intent: French multicenter phase 2 therapeutic trial - NIVOLEPivolumab in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporationMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2017-004679-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)50
Completed
Phase 1
A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinomahepatocellular carcinoma
JPRN-UMIN000029991Yamaguchi University Graduate School of Medicine20
Active, not recruiting
Phase 1
A Study of Nivolumab in Combination with Ipilimumab Compared toNivolumab Alone in Treatment of Patients After Complete Resection ofStage IIIb/c/d or Stage IV Melanoma.Stage IIIb/c/d or Stage IV no evidence of disease (NED) melanomafollowing complete resection of the lesion(s) with high risk of relapse.MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-003729-41-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO1,844